Jul. 26 at 6:10 AM
$ACRV at 1.12/share, trading well below its DCF-derived value of
$4.10, a 266% upside. With
$164.8M in cash—nearly 4x its
$42.95M market cap—and a runway to Q2 2027, ACRV is financially robust. Its pipeline, led by ACR-368 (Phase 2, Fast Track, approval ~2030) and ACR-2316 (Phase 1, ~2031), targets high-value oncology markets. Despite a conservative 5% success probability, positive Phase 2 data could drive significant revaluation. With 60.8% institutional ownership and moderate 4.58% short interest, ACRV offers a high-risk, high-reward opportunity for patient investors.
